Showing results (151-160 of 183) with videos related to
Sort By:
Pageof 19
Archives of Surgery (Chicago, Ill. : 1960)|May 11, 1992
The high-risk liver allograft recipient. Should allocation policy consider outcome?F L Delmonico, R L Jenkins, R Freeman, et al.Annals of Internal Medicine|January 22, 2000
45-year follow-up of hepatitis C virus infection in healthy young adultsL B Seeff, R N Miller, C S Rabkin, et al.Journal of Viral Hepatitis|January 11, 2008
Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirinK R Reddy, S Govindarajan, P Marcellin, et al.Journal of Viral Hepatitis|January 1, 1994
Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy GroupG L Davis, K Lindsay, J Albrecht, et al.The Journal of Infectious Diseases|November 1, 1975
Experimental infection of chimpanzees with hepatitis A virusJ L Dienstag, S M Feinstone, R H Purcell, et al.The New England Journal of Medicine|September 14, 1989
Genetic prediction of nonresponse to hepatitis B vaccineC A Alper, M S Kruskall, D Marcus-Bagley, et al.Annals of Internal Medicine|August 1, 1985
Isolated antibody to hepatitis B surface antigen and response to hepatitis B vaccinationB G Werner, J L Dienstag, B J Kuter, et al.Transplantation|April 1, 1985
Immunogenicity of hepatitis B vaccine in renal transplant recipientsI M Jacobson, G Jaffers, J L Dienstag, et al.The New England Journal of Medicine|April 16, 1987
A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States ArmyL B Seeff, G W Beebe, J H Hoofnagle, et al.Annals of Internal Medicine|July 1, 1984
Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacyJ L Dienstag, B G Werner, B F Polk, et al.Pageof 19